What is the role of the new β-lactam/β-lactamase inhibitors ceftolozane/tazobactam and ceftazidime/avibactam?
出版年份 2016 全文链接
标题
What is the role of the new β-lactam/β-lactamase inhibitors ceftolozane/tazobactam and ceftazidime/avibactam?
作者
关键词
-
出版物
Expert Review of Anti-Infective Therapy
Volume 14, Issue 10, Pages 875-878
出版商
Informa UK Limited
发表日期
2016-09-08
DOI
10.1080/14787210.2016.1233060
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Activity of Ceftazidime-Avibactam against Extended-Spectrum- and AmpC β-Lactamase-Producing Enterobacteriaceae Collected in the INFORM Global Surveillance Study from 2012 to 2014
- (2016) James A. Karlowsky et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program
- (2016) John E. Mazuski et al. CLINICAL INFECTIOUS DISEASES
- Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations
- (2016) David van Duin et al. CLINICAL INFECTIOUS DISEASES
- Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America
- (2016) Tamar F. Barlam et al. CLINICAL INFECTIOUS DISEASES
- Ceftazidime-Avibactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms
- (2016) Roopali Sharma et al. CLINICAL THERAPEUTICS
- Ceftolozane/Tazobactam: A Review in Complicated Intra-Abdominal and Urinary Tract Infections
- (2016) Lesley J. Scott DRUGS
- Treatment options for infections caused by carbapenem-resistantEnterobacteriaceae: can we apply “precision medicine” to antimicrobial chemotherapy?
- (2016) Federico Perez et al. EXPERT OPINION ON PHARMACOTHERAPY
- New β-Lactamase Inhibitors in the Clinic
- (2016) Krisztina M. Papp-Wallace et al. INFECTIOUS DISEASE CLINICS OF NORTH AMERICA
- Antibiotic resistance in Pseudomonas aeruginosa and alternative therapeutic options
- (2016) Maitrayee Chatterjee et al. INTERNATIONAL JOURNAL OF MEDICAL MICROBIOLOGY
- Efficacy of ceftolozane/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTIs) caused by levofloxacin-resistant pathogens: results from the ASPECT-cUTI trial
- (2016) Jennifer A. Huntington et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Access to effective antimicrobials: a worldwide challenge
- (2016) Ramanan Laxminarayan et al. LANCET
- Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study
- (2016) Yehuda Carmeli et al. LANCET INFECTIOUS DISEASES
- Antibiotic resistance in Enterobacteriaceae: mechanisms and clinical implications
- (2016) Jon Iredell et al. BMJ-British Medical Journal
- Antibiotic resistance in Enterobacteriaceae: mechanisms and clinical implications
- (2016) Jon Iredell et al. BMJ-British Medical Journal
- Ceftolozane-tazobactam: A new-generation cephalosporin
- (2015) D. Cluck et al. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
- The Times They Are a-Changin': Carbapenems for Extended-Spectrum-β-Lactamase-Producing Bacteria
- (2015) Jesús Rodríguez-Baño ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Successful Treatment of Carbapenemase-Producing Pandrug-Resistant Klebsiella pneumoniae Bacteremia
- (2015) Jose F. Camargo et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Ceftolozane/Tazobactam Therapy of Respiratory Infections due to Multidrug-ResistantPseudomonas aeruginosa: Table 1.
- (2015) Michael S. Gelfand et al. CLINICAL INFECTIOUS DISEASES
- Treatment of MDR-Gram negative infections in the 21st century: a never ending threat for clinicians
- (2015) Pierluigi Viale et al. CURRENT OPINION IN PHARMACOLOGY
- Fecal microbiota transplantation forClostridium difficileinfection: back to the future
- (2015) Guglielmo Borgia et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- A resurgence of β-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens
- (2015) Karen Bush INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Ceftolozane/tazobactam and ceftazidime/avibactam: two novel β-lactam/β-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections
- (2015) Jordan L. Liscio et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia
- (2015) Alan J. Xiao et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)
- (2015) Florian M Wagenlehner et al. LANCET
- β-lactam and β-lactamase inhibitor combinations in the treatment of extended-spectrum β-lactamase producing Enterobacteriaceae: time for a reappraisal in the era of few antibiotic options?
- (2015) Patrick N A Harris et al. LANCET INFECTIOUS DISEASES
- The β-Lactams Strike Back: Ceftazidime-Avibactam
- (2015) Evan J. Zasowski et al. PHARMACOTHERAPY
- Prescribing Ceftolozane/Tazobactam for Pediatric Patients: Current Status and Future Implications
- (2015) Seetha M. Tamma et al. PEDIATRIC DRUGS
- Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalised with pneumonia in US and European hospitals: Results from the SENTRY Antimicrobial Surveillance Program, 2009–2012
- (2014) Helio S. Sader et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data
- (2014) Thomas P Van Boeckel et al. LANCET INFECTIOUS DISEASES
- Correlations of Antibiotic Use and Carbapenem Resistance in Enterobacteriaceae
- (2013) Milena McLaughlin et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In VitroActivities of Ceftazidime-Avibactam and Aztreonam-Avibactam against 372 Gram-Negative Bacilli Collected in 2011 and 2012 from 11 Teaching Hospitals in China
- (2013) Xiaojuan Wang et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- New β-Lactamase Inhibitors: a Therapeutic Renaissance in an MDR World
- (2013) Sarah M. Drawz et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Structural Insight into Potent Broad-Spectrum Inhibition with Reversible Recyclization Mechanism: Avibactam in Complex with CTX-M-15 and Pseudomonas aeruginosa AmpC β-Lactamases
- (2013) Sushmita D. Lahiri et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Ceftazidime-Avibactam: a Novel Cephalosporin/β-lactamase Inhibitor Combination
- (2013) George G. Zhanel et al. DRUGS
- Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination with Activity Against Multidrug-Resistant Gram-Negative Bacilli
- (2013) George G. Zhanel et al. DRUGS
- Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial
- (2013) Christopher Lucasti et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Efficacy and safety of ceftazidime–avibactam versus imipenem–cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study
- (2012) José A. Vazquez et al. CURRENT MEDICAL RESEARCH AND OPINION
- Affinity of the New Cephalosporin CXA-101 to Penicillin-Binding Proteins of Pseudomonas aeruginosa
- (2010) B. Moya et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now